Researchers have developed the first reliable test for new variant Creutzfeldt-Jakob disease (CJD) that can be used while the patient is still alive. Details are revealed in this week's Lancet. The test, developed under John Collinge at Imperial College, London, identifies rogue prion proteins in tonsil tissue and means doctors could test the general population.